Kos Settlement Keeps Barr’s Generic Niaspan, Advicor Off Market Until 2013

The generic firm’s decision to settle appears to have been influenced by a federal appeals court’s recent decision to rescind an earlier ruling on “public use” and patent invalidity in the Paxil case. Barr could enter the market before 2013 if another ANDA product launches.